ProQuad

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
22-07-2022

Ingredient activ:

virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella

Disponibil de la:

Merck Sharp & Dohme B.V.

Codul ATC:

J07BD54

INN (nume internaţional):

measles, mumps, rubella and varicella vaccine (live)

Grupul Terapeutică:

Vaccines

Zonă Terapeutică:

Chickenpox; Rubella; Measles; Mumps; Immunization

Indicații terapeutice:

ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.,

Rezumat produs:

Revision: 31

Statutul autorizaţiei:

Authorised

Data de autorizare:

2006-04-05

Prospect

                                38
B. PACKAGE LEAFLET
39
PACKAGE LE
AFLET: INFORMATION FOR THE USER
PROQUAD
POWDER AND SO
LVENT FOR SUSPENSION FOR INJECTION
Measles, mumps, rubella and varicella vac
cine (live)
R
EAD ALL OF THIS LEAFLE
T CAREFULLY BEFORE YOU OR YO
UR CHILD IS VACCINA
TED
BECAUSE IT CONTAINS
IMPORTANT INFORMATI
ON FOR YOU.
-
Keep this leaflet. You may ne
ed to read it again.
-
If you have any further questions, ask your doctor or your pharm
acist.
-
This
vaccine has been presc
ribed for you o
r your child
only. Do not pass i
t on to others.
-
If you get any of the sid
e effects, talk to your doctor or pharmacis
t. This inc
ludes any possible
side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pro
Quad is and wha
t it is used for
2.
What you need
to know before you receive ProQuad
3.
How
to use ProQuad
4.
Possible side effects
5.
How to store ProQuad
6.
Contents of the pack and other information
1.
WHAT PROQUAD I
S AND WHAT IT IS USED FOR
ProQuad
is a vaccine co
ntaining meas
les, mumps, rubella,
and chickenpox (varicella) viruses that
h
ave been weakened. When
a person is
given the vaccine, the immune system (the body’s natural
defences
) will make antibodies agains
t the measles,
mumps, rubella, and
varicella viruses. The
antibo
dies help protect against diseases caused by these viruses.
P
roQuad is given to help
protect you
r child against measles, mumps, rubella
, and chickenpox
(varicella)
. The vaccine may be adminis
tered to perso
ns from 12 months of
age.
ProQuad ma
y also be adm
inistered to infants from 9 months of age under special circum
stances (to
co
nform with national vaccination schedules, outbreak situatio
ns, or travel to a
region with high
prevalence of measle
s).
Although
ProQuad contains liv
e
viruses, they a
re too weak t
o cause measles, mumps, rubella, or
chickenpox (varicella) in
healthy people.
2.
WHAT YOU NEED TO KNOW BEFORE YOU
RECEIVE PROQUAD
DO
NOT USE PROQUAD

If the person to be vaccinated is aller
gic to any varicella
vaccine or mea
sles, mumps, or rubella
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY
OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ProQuad powder and solvent for suspension for injection
ProQuad powder and solvent for suspension for
injection in a pre-filled syringe
Measles, mump
s,
rubella and varicella vaccin
e (live).
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
After reconstitution, one dose (0.5
mL) contains:
Measles virus
1
Enders’ Edmonston strain (live, attenuated)
........ not less than 3.00 log
10
TCID
50
*
Mumps virus
1
Jeryl Lynn
™
(Le
vel B) strain (live, attenua
ted) ...
not less than 4.30 log
10
TCID
50
*
Rubella virus
2
Wistar RA 27/3 strain (live, attenuated)
...............
not less than 3.00 log
10
TCID
50
*
Varicella virus
3
Oka/Merck strain (live, attenuat
ed) ...................
not less than 3.99 log
10
PFU**
*50% tissue cultur
e infectious dose
**plaque-f
orming units
(
1
) Produced in chick embryo cells.
(
2
) Produced in human diploid lung (WI
-38) fibroblasts.
(
3
) Produced in human diploid (MRC
-5) cells.
The vaccine may contain
traces of recombinant human alb
umin (rHA).
This vacc
ine contains a trace amount
of neomycin. See section 4.3.
Excipient(s)
with known effect
The vaccine contains 16
milligrams
of sorbitol per dose.
See section 4.4.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solve
nt for suspension for injection
Before r
econstitution, the pow
der is a white to pale yellow
compact
crystalline cake and the solvent is
a clear colourless liquid.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
ProQuad is indicated for simultaneous
vaccination against measles, mumps, rub
ella and varicella in
individuals from 12
months of age.
ProQuad
can be administered to individuals from 9
months of
age under special circumstances (e.g.,
to conform with national vaccination sche
dules, outbreak
situations, or travel to a region with hig
h
prevalence of measle
s; see sections 4.2, 4.4, and
5.1).
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
ProQu
ad should be used in accordance to official r
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului bulgară 22-07-2022
Raport public de evaluare Raport public de evaluare bulgară 08-10-2020
Prospect Prospect spaniolă 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului spaniolă 22-07-2022
Raport public de evaluare Raport public de evaluare spaniolă 08-10-2020
Prospect Prospect cehă 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului cehă 22-07-2022
Raport public de evaluare Raport public de evaluare cehă 08-10-2020
Prospect Prospect daneză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului daneză 22-07-2022
Raport public de evaluare Raport public de evaluare daneză 08-10-2020
Prospect Prospect germană 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului germană 22-07-2022
Raport public de evaluare Raport public de evaluare germană 08-10-2020
Prospect Prospect estoniană 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului estoniană 22-07-2022
Raport public de evaluare Raport public de evaluare estoniană 08-10-2020
Prospect Prospect greacă 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului greacă 22-07-2022
Raport public de evaluare Raport public de evaluare greacă 08-10-2020
Prospect Prospect franceză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului franceză 22-07-2022
Raport public de evaluare Raport public de evaluare franceză 08-10-2020
Prospect Prospect italiană 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului italiană 22-07-2022
Raport public de evaluare Raport public de evaluare italiană 08-10-2020
Prospect Prospect letonă 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului letonă 22-07-2022
Raport public de evaluare Raport public de evaluare letonă 08-10-2020
Prospect Prospect lituaniană 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului lituaniană 22-07-2022
Raport public de evaluare Raport public de evaluare lituaniană 08-10-2020
Prospect Prospect maghiară 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului maghiară 22-07-2022
Raport public de evaluare Raport public de evaluare maghiară 08-10-2020
Prospect Prospect malteză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului malteză 22-07-2022
Raport public de evaluare Raport public de evaluare malteză 08-10-2020
Prospect Prospect olandeză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului olandeză 22-07-2022
Raport public de evaluare Raport public de evaluare olandeză 08-10-2020
Prospect Prospect poloneză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului poloneză 22-07-2022
Raport public de evaluare Raport public de evaluare poloneză 08-10-2020
Prospect Prospect portugheză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului portugheză 22-07-2022
Raport public de evaluare Raport public de evaluare portugheză 08-10-2020
Prospect Prospect română 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului română 22-07-2022
Raport public de evaluare Raport public de evaluare română 08-10-2020
Prospect Prospect slovacă 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului slovacă 22-07-2022
Raport public de evaluare Raport public de evaluare slovacă 08-10-2020
Prospect Prospect slovenă 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului slovenă 22-07-2022
Raport public de evaluare Raport public de evaluare slovenă 08-10-2020
Prospect Prospect finlandeză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului finlandeză 22-07-2022
Raport public de evaluare Raport public de evaluare finlandeză 08-10-2020
Prospect Prospect suedeză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului suedeză 22-07-2022
Raport public de evaluare Raport public de evaluare suedeză 08-10-2020
Prospect Prospect norvegiană 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului norvegiană 22-07-2022
Prospect Prospect islandeză 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului islandeză 22-07-2022
Prospect Prospect croată 22-07-2022
Caracteristicilor produsului Caracteristicilor produsului croată 22-07-2022
Raport public de evaluare Raport public de evaluare croată 08-10-2020

Vizualizați istoricul documentelor